NCT06279767View on ClinicalTrials.gov

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 1, 2025

Study Completion Date

July 31, 2025

Conditions
GlioblastomaCancerTemozolomide
Interventions
DRUG

6-mercaptopurine

6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.

Trial Locations (1)

210029

RECRUITING

Department of Neurosurgery of The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER